Edding Genor Expands Global Rights to Key siRNA Drug as It Streamlines Nanopeptide Collaboration

Genor Biopharma Holdings Limited ( (HK:6998) ) has issued an update.

Edding Genor Group Holdings has restructured its collaboration with Nanopeptide, expanding the territorial scope of its key siRNA asset targeting ANGPTL3 from selected regions to worldwide, and securing global patent rights to the molecule while jointly owning the GalNAc platform technology. The move strengthens the strategic importance of ANGPTL3 within the company’s pipeline, where lead candidate EDP167 has begun phase II trials, and is expected to enhance long-term shareholder value.

At the same time, Edding Genor and Nanopeptide have terminated cooperation on two other pre-clinical siRNA assets, a decision the company attributes to a competitive market landscape and the early development stage of those programs. Management emphasized that discontinuing these projects should not materially affect the group’s business, financial condition or operations, suggesting a focused capital allocation strategy around its most promising RNA therapy asset.

The most recent analyst rating on (HK:6998) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Genor Biopharma Holdings Limited stock, see the HK:6998 Stock Forecast page.

More about Genor Biopharma Holdings Limited

Edding Genor Group Holdings Limited is a biopharmaceutical company focused on the development, manufacturing and commercialisation of innovative drug candidates, including RNA-based therapies such as small interfering RNA (siRNA) assets. The group targets global markets for cardiovascular and metabolic disease treatments, with a growing pipeline led by its ANGPTL3-targeting candidate EDP167.

Average Trading Volume: 1,338,171

Technical Sentiment Signal: Hold

Current Market Cap: HK$5.26B

For an in-depth examination of 6998 stock, go to TipRanks’ Overview page.